No abstract available.
Fetal Blood* ; Stem Cells*

No abstract available.

PURPOSE: For the synthesis of surfactant protein(SP) peptides and production of next generation artificial pulmonary surfactant(PS), we have isolated SP-B, C from bovine PS, and studied the biochemical properties and amino acid sequences of these protein-peptides. METHODS: Crude surfactant and purified surfactant were isolated from materials extracted from the bovine lung lavage. The hydrophobic SP-B, C were purified by Sephadex LH 60 column chromatography from PS. The purities of SP-B, C were assessed by tricine buffer SDS-polyacrylamide gel electrophoresis and the amino acid sequences of these proteins were determined using Beckman PI-2090. RESULTS: The molecular weights of SP-B, C shown in SDS-polyacrylamide gel electrophoresis were as follows; 15,000-18,000(oligomer) Da for SP-B, 3,500-5,000 Da for SP-C. The amino acid sequences were; FPIPLPYCWL LRTLIKKIQA VIPKGVLAMT VAQCHVVPL LVGGIQQLV IEYSVILLTD TLLGRLPNLV CGLRLRCSG in SP-B, LIPCCPVNIK RLLIVVVVVV LLVVVIVGAL LMGL in SP-C, respectively. These results indicated that the amino acid sequences of bovine SPs were different. CONCLUSION: The SP-B, C were purified from bovine PS, and amino acid sequences of SP-B, C were determined. Further studies are needed for the development and use of next generations of exogenous PS preparation based on synthetic SP-peptides for the treatment of neonatal RDS in the future.
Amino Acid Sequence* ; Bronchoalveolar Lavage ; Chromatography ; Electrophoresis ; Family Characteristics ; Humans ; Infant, Newborn ; Molecular Weight ; Peptides ; Pulmonary Surfactants*

Hemophilia A is a bleeding disorder resulting from a congenital deficiency of factor VIII. The mainstay of successful hemophilia therapy for either treatment or prevention of acute hemorrage is prompt and sufficient intravenous replacement of factor VIII to hemostatic levels. One of the most serious complications of hemophilia and its therapy is the development of polyclonal antibodies to factor VIII that neutralize factor coagulant activity. APCCs is otherwise known as bypass therapy, products that bypass the requirement for factor VIII for clot formation and moderately effective in controlling bleeding in high inhibitor patients. We experienced a case of hemophilia A with high inhibitor titer in a 13 year-old boy who presented with incarcerated right inguinal hernia and a successful therapeutic effect of APCCs(Autoplex) for controlling post-operative hemorrhages.
Adolescent ; Antibodies ; Factor VIII ; Hemophilia A* ; Hemorrhage ; Hernia, Inguinal ; Humans ; Male

No abstract available.
Precursor Cell Lymphoblastic Leukemia-Lymphoma*

No abstract available.
gamma-Globulins* ; Purpura, Thrombocytopenic, Idiopathic*

No abstract available.
Child* ; Humans ; Purpura, Thrombocytopenic, Idiopathic*

No abstract available.
Humans ; Killer Cells, Lymphokine-Activated* ; Killer Cells, Natural*

No abstract available.
Anemia, Iron-Deficiency* ; Ferritins* ; Iron*

No abstract available.
Humans ; Infant, Newborn*